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Acute coronary syndrome in HIV-infected patients.
Does it differ from that in the general population?
Syndrome coronaire aigu chez le patient infecté par le VIH : existent-ils des
différences avec la population générale ?
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Cardiovascular disease, and particularly coronary artery disease-related morbidity, has
become the fourth most common cause of death in HIV-infected patients in France
[1] and the third most common cause in the United States [2]. Since the advent of
a potent antiretroviral therapy in the mid 1990s, HIV infection has become a chronic
rather than a fatal disease. The life expectancy of a young HIV-infected patient with-
out hepatitis co-infection is today more than 35 years [3]. In developed countries, the
causes of death in HIV-infected patients besides AIDS-related morbidity (still the pri-
mary cause of death usually related to late diagnosis of HIV) are similar to those of
uninfected patients (e.g., non-AIDS neoplastic disease, cardiovascular disease, hepati-
tis). However, these complications tend to emerge earlier (around 10 years) than in the
general population, suggesting an acceleration of ageing in patients infected with HIV.
Premature and acceleration of atherosclerosis are, therefore, an emerging complication
in HIV.
Recently, Lang et al. [4] estimated the incidence of myocardial infarction in HIV-infected
patients in comparison with the general population. The sex- and age-standardized mor-
bidity ratio was estimated as 1.5 (95% conﬁdence interval [CI] 1.3—1.7]) overall, 1.4 (95%
CI 1.3—1.6) in men and 2.7 (95% CI 1.8—3.9) in women. Similar results were observed in
the North American population [5]. Of note is the young age at which myocardial infarc-Virus de
l’immunodéﬁcience
humaine ;
Traitement
antirétroviral
tion occurred. In two recent French studies, the median age at which a ﬁrst episode of
acute coronary syndrome (ACS) occurred was around 48 years [6,7]. Besides the increased
incidence and premature occurrence of myocardial infarction in the HIV-infected popula-
tion compared with the general population, are there speciﬁc risk factors that can explain
these differences?
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When considering cardiovascular risk factors, in the prog-
osis of acute coronary syndrome in HIV-infected patients
PACS) study [7], HIV-infected patients with ACS were
requently current smokers (60%), dyslipidaemic (50%),
ypertensive (20%) and diabetic (10%), but these differences
anished when the population was matched for age with
ninfected patients [7]. Only hypertriglyceridaemia and
llicit drug use (particularly cocaine) were more frequent in
IV-infected patients with an ACS compared with the gen-
ral population. The question is, do these factors explain
he higher rate and premature occurrence of myocardial
nfarction in HIV-infected patients? The process is likely to be
ultifactorial, involving a combination of chronic HIV infec-
ion along with low-grade persistent inﬂammation, immune
ysregulation, antiretroviral therapy and related metabolic
isturbances such as insulin resistance, dyslipidaemia and
ipodystrophy. In the PACS study [7], the angiographic char-
cteristics of ACS in HIV-infected patients were similar to
hose of uninfected patients, with predominant single-vessel
isease and preserved left ventricular ejection fraction, in
greement with the characteristics reported in the young
opulation with ACS.
The results of immediate coronary revascularization,
hether by percutaneous coronary intervention and/or
oronary artery bypass graft surgery, are excellent in this
opulation, with no difference with the general popula-
ion [7—13]. In the PACS study [7], the success of PCI was
reater than 94%, with no difference in the rates of acute
tent thrombosis. One acute stent thrombosis occurred at
ay 5 in an HIV-infected patient and another at day 1 in an
ninfected patient. No additional cases of stent thrombo-
is occurred in the subsequent 12 months. The HIV-infected
atients were well treated for HIV, with 69% of the entire
ohort having an HIV viral load less than 200 copies/mL,
uggesting that these patients adhered to their therapeutic
rug regimens. These data should allay fears about implant-
ng a drug-eluting stent followed by long-term treatment
ith dual antiplatelet therapy in this population. However,
fter 1-year of follow-up in the PACS study, recurrent ACS
as more frequent in the HIV-infected population compared
ith the controls (hazard ratio 6.5, 95% CI 1.7—23.9), but of
he rates of recurrent revascularization did not differ. This
iscrepancy was due to the higher rate of silent myocar-
ial ischaemia detected in the controls. In fact, the rate of
tress testing after ACS was more frequent in the controls
han in patients infected with HIV (80 vs. 63%, p = 0.004),
nd this could have led to a bias in the rate of recurrent
evascularization, with an overestimation in the controls.
ndeed, the rate of repeat urgent revascularization driven
y recurrent ACS was higher in HIV-infected patients (odds
atio 3.29, 95% CI 0.94—11.53, p = 0.06). The rate of clini-
al restenossis??? Surprisingly, the rate of smoking cessation
as lower in HIV-infected patients than in controls (51 vs.
0%, p = 0.002), along with persistent atherogenic dyslipi-
aemia in HIV-infected patients (total cholesterol 2.22± 2.4
s. 1.73± 4.8 g/L, p = 0.046; non—high-density lipoprotein
holesterol 1.53± 4.7 vs. 1.25± 4.4 g/L, p = 0.020; total
holesterol/high-density lipoprotein cholesterol 5.3± 3.3
s. 3.8± 1.3, p = 0.004). Whether these two factors will lead
o an increased rate of recurrent ACS in the long-term will
e evaluated after 3 years of follow-up, the data for which
ill become available next year.F. Boccara
In conclusion, ACS is more frequent and occurs earlier in
he HIV-infected population than in the general population.
raditional risk factors are frequent, particularly tobacco
moking. Screening for illicit drug use, especially cocaine,
hould be done immediately after the onset of symptoms in
his young population. Coronary revascularization, whether
ercutaneous coronary intervention and/or coronary artery
ypass graft, can be performed safely and with excellent
nitial results, with no reports of an increased rate of stent
hrombosis. The mid-term prognosis seems to be worse in
he HIV-infected population, with a higher rate of recurrent
CS, suggesting failure to control the atherothrombotic pro-
ess. This is probably due to the persistently higher rate
f current smokers and uncontrolled dyslipidaemia after
CS. However, many factors could inﬂuence the prognosis,
uch as the HIV infection itself, low-grade inﬂammation or
ntiretroviral therapy. In secondary prevention, awareness
f smoking cessation and achieving target lipid concentra-
ions (two modiﬁable cardiovascular risk factors) should be
ade in the HIV-infected population to decrease the higher
ate of recurrent ischaemic events.
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